Luis Gabriel Vázquez-Lavista

Dr. Luis Gabriel Vázquez-Lavista

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2009 in Urology
Verified
Journal Article
Closed access
LVLuis Gabriel Vázquez-Lavista
Luis Gabriel Vázquez-Lavista
GLGuadalupe Lima
Guadalupe Lima
FGFernando Gabilondo
Fernando Gabilondo
LLLuis Llorente
Luis Llorente

1 June 2014 in Urology
Verified
Journal Article
Closed access
DODaniel Olvera-Posada
Daniel Olvera-Posada
GAGhislaine Armengod-Fischer
Ghislaine Armengod-Fischer
LVLuis Gabriel Vázquez-Lavista
Luis Gabriel Vázquez-Lavista
MMMiguel Maldonado-Ávila
Miguel Maldonado-Ávila
EREmmanuel Rosas-Nava
Emmanuel Rosas-Nava
FRFrancisco T. Rodríguez-Covarrubias
Francisco T. Rodríguez-Covarrubias

21 November 2022 in Current Urology
Verified
Journal Article
Open access
HTHegel Trujillo-Santamaría
Hegel Trujillo-Santamaría
JRJosé Iván Robles-Torres
José Iván Robles-Torres
Jeremy Yuen Chun TeohJeremy Yuen Chun Teoh
Jeremy Yuen Chun Teoh
YTYiloren Tanidir
Yiloren Tanidir
JCJosé Gadú Campos-Salcedo
José Gadú Campos-Salcedo
Vineet GauharVineet Gauhar
Vineet Gauhar
Background: Emphysematous pyelonephritis (EPN) is a necrotizing infection of the kidney and the surrounding tissues associated with considerable mortality. We aimed to formulate a score that classifies the risk of mortality in patients with EPN at hospital admission. Materials and methods: Patients diagnosed with EPN between 2013 and 2020 were retrospectively included. Data from 15 centers (70%) were used to develop the scoring system, and data from 7 centers (30%) were used to validate it. Univariable and multivariable logistic regression analyses were performed to identify independent factors related to mortality. Receiver operating characteristic curve analysis was performed to construct the scoring system and calculate the risk of mortality. A standardized regression coefficient was used to quantify the discriminating power of each factor to convert the individual coefficients into points. The area under the curve was used to quantify the scoring system performance. An 8-point scoring system for the mortality risk was created (range, 0–7). Results: In total, 570 patients were included (400 in the test group and 170 in the validation group). Independent predictors of mortality in the multivariable logistic regression were included in the scoring system: quick Sepsis-related Organ Failure Assessment score ≥2 (2 points), anemia, paranephric gas extension, leukocyte count >22,000/μL, thrombocytopenia, and hyperglycemia (1 point each). The mortality rate was <5% for scores ≤3, 83.3% for scores 6, and 100% for scores 7. The area under the curve was 0.90 (95% confidence interval, 0.84–0.95) for test and 0.91 (95% confidence interval, 0.84–0.97) for the validation group. Conclusions: Our score predicts the risk of mortality in patients with EPN at presentation and may help clinicians identify patients at a higher risk of death.

10 November 2005 in Hernia
Verified
Journal Article
Closed access
PDF file
LVLuis Gabriel Vázquez-Lavista
Luis Gabriel Vázquez-Lavista
CPC. Pérez-Pruna
C. Pérez-Pruna
CFChristian Haydee Flores-Balcázar
Christian Haydee Flores-Balcázar
GGG. Guzmán-Valdivia
G. Guzmán-Valdivia
ERE. Romero-Arredondo
E. Romero-Arredondo
JOJ. B. Ortiz-López
J. B. Ortiz-López

1 July 2009 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
ESElena Soto-Vega
Elena Soto-Vega
CACarlos Arroyo
Carlos Arroyo
YRYvonne Richaud-Patin
Yvonne Richaud-Patin
MGMario García-Carrasco
Mario García-Carrasco
LVLuis Gabriel Vázquez-Lavista
Luis Gabriel Vázquez-Lavista
LLLuis Llorente
Luis Llorente

1 July 2008 in Urologia Internationalis
Verified
Journal Article
Closed access
LVLuis Gabriel Vázquez-Lavista
Luis Gabriel Vázquez-Lavista
NUN. Uribe-Uribe
N. Uribe-Uribe
FGF. Gabilondo-Navarro
F. Gabilondo-Navarro
Collecting duct carcinoma (CDC) of Bellini is a rare variant of renal cell carcinoma. It tends to be more aggressive when locally advanced or when having distant spread on diagnosis. The only favorable prognosis factor is low-stage, low-grade, with disease-free survival reported up to 5 years. We reviewed our renal cell carcinoma database and found 2 cases of CDC, namely 1 young female with locally advanced disease with supraclavicular metastasis and a dismissal prognosis, and 1 male with localized disease with 10-year disease-free survival.